007570.KS

Ilyang Pharmaceutical Co.,Ltd [007570.KS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

007570.KS Stock Summary

Earnings are expected to fall -100% next year

007570.KS has less than 1 year of cash runway

Top 10 Correlated ETFs

007570.KS

Top 10 Correlated Stocks

007570.KS

In the News

007570.KS Financial details

Company Rating

Neutral

Market Cap

252.86B

Income

-2.55B

Revenue

370.54B

Book val./share

12628.51

Cash/share

1052.11

Dividend

Dividend %

Employees

655

Optionable

Shortable

Yes

Earnings

13 May 2024

P/E

33.08

Forward P/E

PEG

-3.06

P/S

0.73

P/B

1.16

P/C

13.16

P/FCF

-268.22

Quick Ratio

Current Ratio

0.89

Debt / Equity

0.37

LT Debt / Equity

0.02

EPS (TTM)

-142.06

EPS next Y

EPS next Q

EPS this Y

-107.94%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

2.68%

Revenue Q/Q

3.57%

EPS Q/Q

-252.72%

SMA20

-1.91%

SMA50

-3.29%

SMA100

-4.91%

Inst Own

Inst Trans

ROA

ROE

ROC

0.07%

Gross Margin

54%

Oper. Margin

Profit Margin

Payout

47%

Shs Outstand

Shs Float

Target Price

52W Range

13130.0-18430.0

52W High

-24.85%

52W Low

+5.48%

RSI

Rel Volume

0.63

Avg Volume

26.72K

Volume

16.89K

Perf Week

-1.7%

Perf Month

-1.07%

Perf Quarter

0.07%

Perf Half Y

-1.42%

Beta

-0.274

Volatility

104.8%, 279.37%

Prev Close

Price

13850

Change

0.36%

007570.KS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	17.83K	18.86K	20.4K	21.18K	20.56K
Net income per share	1.08K	1.18K	1.43K	1.75K	-139.1
Operating cash flow per share	1.99K	3.16K	3.68K	1.65K	1.08K
Free cash flow per share	1.53K	1.81K	2.51K	518.65	409.43
Cash per share	1.97K	2.29K	4.51K	3.59K	1.05K
Book value per share	10.82K	11.38K	12.31K	12.95K	12.6K
Tangible book value per share	9.38K	10.19K	11.35K	11.97K	13.08K
Share holders equity per share	10.82K	11.38K	12.31K	12.95K	12.6K
Interest debt per share	7.29K	5.83K	5.72K	4.86K	4.91K
Market cap	410.53B	1197.9B	510.66B	342.57B	286.68B
Enterprise value	503.2B	1259.6B	565.01B	368.69B	362.35B
P/E ratio	20.95	55.6	19.67	10.79	-114.38
Price to sales ratio	1.26	3.49	1.38	0.89	0.77
POCF ratio	11.34	20.84	7.62	11.44	14.79
PFCF ratio	14.76	36.45	11.18	36.44	38.86
P/B Ratio	2.08	5.78	2.28	1.46	1.26
PTB ratio	2.08	5.78	2.28	1.46	1.26
EV to sales	1.55	3.67	1.52	0.96	0.98
Enterprise value over EBITDA	11.83	27.25	10.57	6.48	10.92
EV to operating cash flow	13.9	21.91	8.43	12.32	18.7
EV to free cash flow	18.1	38.33	12.37	39.22	49.12
Earnings yield	0.05	0.02	0.05	0.09	-0.01
Free cash flow yield	0.07	0.03	0.09	0.03	0.03
Debt to equity	0.65	0.5	0.46	0.37	0.37
Debt to assets	0.29	0.23	0.21	0.17	0.18
Net debt to EBITDA	2.18	1.34	1.02	0.46	2.28
Current ratio	0.95	0.92	1.03	1.07	0.94
Interest coverage	7.68	11.3	19.93	16.43	6.72
Income quality	1.85	2.67	2.58	0.94	-7.73
Dividend Yield	0.01	0	0.02	0.01	0.01
Payout ratio	0.3	0.23	0.34	0.12	-1.55
Sales general and administrative to revenue	0.06	0.02	0.02	0.02	0.02
Research and developement to revenue	0.05	0.06	0.05	0.07	0.07
Intangibles to total assets	0.12	0.14	0.13	0.15	0.06
Capex to operating cash flow	-0.23	-0.43	-0.32	-0.69	-0.62
Capex to revenue	-0.03	-0.07	-0.06	-0.05	-0.03
Capex to depreciation	-0.83	-1.94	-1.69	-1.57	-1.43
Stock based compensation to revenue	0	0	0	0	0
Graham number	16.18K	17.41K	19.87K	22.59K	6.28K
ROIC	0.07	0.08	0.08	0.1	0
Return on tangible assets	0.05	0.06	0.06	0.07	-0.01
Graham Net	-5.03K	-4.16K	-3.3K	-3.06K	-5.79K
Working capital	-8.92B	-14.65B	5.35B	13.87B	-10.8B
Tangible asset value	170.74B	185.52B	206.59B	216.96B	235.77B
Net current asset value	-43.31B	-31.7B	-18.95B	-5.6B	-42.83B
Invested capital	0.65	0.5	0.46	0.37	0.37
Average receivables	81.72B	75.38B	74.86B	76.66B	71.32B
Average payables	23.61B	24.47B	25.26B	32.24B	34.56B
Average inventory	51.5B	51.02B	44.89B	51.28B	61.55B
Days sales outstanding	90.78	74.45	78.33	70.02	67.97
Days payables outstanding	63.26	53.44	58.72	81.86	67
Days of inventory on hand	133.81	109.73	90.06	133.51	131.31
Receivables turnover	4.02	4.9	4.66	5.21	5.37
Payables turnover	5.77	6.83	6.22	4.46	5.45
Inventory turnover	2.73	3.33	4.05	2.73	2.78
ROE	0.1	0.1	0.12	0.14	-0.01
Capex per share	-460.6	-1.35K	-1.17K	-1.13K	-666.24

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	5.59K	4.44K	4.73K	5.6K	5.8K
Net income per share	187.02	161.15	-161.46	268.87	-410.62
Operating cash flow per share	631.01	-294.53	129.27	305.8	939.28
Free cash flow per share	509.83	-513.68	-5.17	270.65	661.98
Cash per share	3.59K	826.66	819.25	912.94	1.05K
Book value per share	12.97K	12.11K	12.75K	13.09K	12.63K
Tangible book value per share	12K	9.84K	10.52K	10.92K	14.64K
Share holders equity per share	12.97K	12.11K	12.75K	13.09K	12.63K
Interest debt per share	4.78K	5.03K	5.43K	5.22K	4.77K
Market cap	341.84B	304.04B	309.29B	251.63B	285.93B
Enterprise value	367.96B	385.75B	395.46B	334.96B	361.61B
P/E ratio	25.26	26.08	-26.54	13.02	-9.69
Price to sales ratio	3.38	3.79	3.62	2.5	2.74
POCF ratio	29.95	-57.07	132.59	45.78	16.94
PFCF ratio	37.07	-32.72	-3.32K	51.73	24.03
P/B Ratio	1.46	1.39	1.34	1.07	1.26
PTB ratio	1.46	1.39	1.34	1.07	1.26
EV to sales	3.64	4.8	4.63	3.33	3.47
Enterprise value over EBITDA	40.45	9.14	7.86	6.35	31.18
EV to operating cash flow	32.24	-72.41	169.54	60.94	21.42
EV to free cash flow	39.9	-41.52	-4.24K	68.86	30.39
Earnings yield	0.01	0.01	-0.01	0.02	-0.03
Free cash flow yield	0.03	-0.03	0	0.02	0.04
Debt to equity	0.37	0.42	0.42	0.39	0.37
Debt to assets	0.17	0.2	0.21	0.19	0.18
Net debt to EBITDA	2.87	1.94	1.71	1.58	6.52
Current ratio	1.07	0.85	0.85	0.89	0.94
Interest coverage	7.43	-101.18	1.84	7.88	10.67
Income quality	3.37	-1.74	-1.12	1.04	-2.29
Dividend Yield	0	0	0.01	0	0
Payout ratio	0	0.07	-1.27	0	0
Sales general and administrative to revenue	0.02	0.47	0.56	0.44	0
Research and developement to revenue	0.07	0.08	0.09	0.07	0.06
Intangibles to total assets	0.15	0.17	0.16	0.15	0.16
Capex to operating cash flow	-0.19	0.74	-1.04	-0.11	-0.3
Capex to revenue	-0.02	-0.05	-0.03	-0.01	-0.05
Capex to depreciation	-0.66	-1.15	-0.73	-0.19	-2.39
Stock based compensation to revenue	0	0	0	0	0
Graham number	7.39K	6.63K	6.81K	8.9K	10.8K
ROIC	0.01	0.01	0.03	0.02	0.02
Return on tangible assets	0.01	0.01	-0.01	0.01	-0.02
Graham Net	-3.06K	-5.18K	-5.5K	-5.61K	-5.81K
Working capital	13.87B	-26.47B	-26.42B	-21.22B	-10.8B
Tangible asset value	216.96B	178.03B	189.76B	196.19B	187.5B
Net current asset value	-5.6B	-44.38B	-47.26B	-41.62B	-42.83B
Invested capital	0.37	0.42	0.42	0.39	0.37
Average receivables	78.73B	70.18B	64.3B	73.62B	77.19B
Average payables	35.79B	34.08B	29.21B	35B	36.8B
Average inventory	59.84B	62.49B	67.21B	71.89B	67.35B
Days sales outstanding	65.53	74.77	65.24	76.35	59.59
Days payables outstanding	71.72	72.09	71.7	79.09	57.09
Days of inventory on hand	116.97	150.25	181.97	137.08	111.88
Receivables turnover	1.37	1.2	1.38	1.18	1.51
Payables turnover	1.25	1.25	1.26	1.14	1.58
Inventory turnover	0.77	0.6	0.49	0.66	0.8
ROE	0.01	0.01	-0.01	0.02	-0.03
Capex per share	-121.18	-219.14	-134.44	-35.16	-277.3

007570.KS Frequently Asked Questions

What is Ilyang Pharmaceutical Co.,Ltd stock symbol ?

Ilyang Pharmaceutical Co.,Ltd is a KR stock and trading under the symbol 007570.KS

What is Ilyang Pharmaceutical Co.,Ltd stock quote today ?

Ilyang Pharmaceutical Co.,Ltd stock price is $13850 today.

Is Ilyang Pharmaceutical Co.,Ltd stock public?

Yes, Ilyang Pharmaceutical Co.,Ltd is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 26.72K
Market Capitalization 252.86B
Employee 655
CEO Mr. Dong-Yeon Kim
Headquarters Yongin,KR
IPO Date 2000-01-04
Website https://www.ilyang.co.kr

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and beverages. In addition, the company offers pharmaceutical raw materials products, such as aluminum hydroxide gel, dried aluminum hydroxide gel, magnesium hydroxide, magnesium hydroxide gel, aluminum hydroxide-magnesium carbonate co-dried gel, magnesium trisilicate, hydrotalcite, almagate, aluminum phosphate, aluminum phosphate gel, aluminum magnesium metasilicate, aluminum magnesium silicate, aluminum magnesium silicopolydrate, magaldrate, magaldrate wet gel, dihydroxy aluminum sodium carbonate, magnesium carbonate, aluminum magnesium hydroxide, synthetic aluminum silicate, and other products. Ilyang Pharmaceutical Co.,Ltd also exports its products to approximately 14 countries. The company was formerly known as Il-Yang Pharm. Ind. Co. and changed its name to Ilyang Pharmaceutical Co., Ltd. in May 1991. Ilyang Pharmaceutical Co.,Ltd was founded in 1946 and is headquartered in Yongin, South Korea.